Trials / Completed
CompletedNCT00651105
Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects
A Double-blind, Placebo-controlled, Randomized, Cross-over Study to Evaluate the GLP-1-mediated and Non-GLP-1-mediated Effects of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 63 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the GLP-1 and non-GLP-1 effects of LAF237 on glucagon secretion, using treatment observations of the overall glycemic response.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vildagliptin | |
| DRUG | Placebo |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2009-05-01
- First posted
- 2008-04-02
- Last updated
- 2016-11-18
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00651105. Inclusion in this directory is not an endorsement.